Visceral Fat and Biological Ageing: New Research Links Deep Belly Fat to Faster Cellular Ageing
Key Takeaways:
- A study of nearly 4,800 adults aged 45 to 69 from the Busselton Healthy Ageing Study found that higher levels of visceral fat – the fat stored deep within the abdomen – were associated with faster biological and cellular ageing in both men and women.
- Among female participants, greater visceral fat was also linked to shorter telomere length, a recognised marker of cellular ageing.
- The associations held even after researchers adjusted for overall body fat, body mass index (BMI), waist circumference and lifestyle factors, suggesting visceral fat exerts an effect beyond general measures of body composition.
New research from The University of Western Australia suggests that visceral fat, the type of fat stored deep within the abdominal cavity and wrapped around internal organs, may contribute to faster biological ageing in middle-aged adults independently of overall body weight or general obesity measures. The findings were published in the journal Obesity.
A large population-based analysis
The study was co-authored by Adjunct Associate Professors Jennie Hui and Kun Zhu, both of The University of Western Australia, with the analysis led by Mr Riorden O’Shea, a resident medical officer with the WA Country Health Service. Researchers drew on data from nearly 4,800 participants – 2,614 of them women – aged between 45 and 69 years, all enrolled in the Busselton Healthy Ageing Study.
The team examined how visceral fat related to markers of biological ageing, including indicators of cellular ageing such as telomere length. Telomeres are the repetitive DNA sequences that cap the ends of chromosomes; their progressive shortening over time is widely regarded as a key biological signature of cellular ageing.
The analysis found that greater visceral fat was associated with accelerated biological ageing in both men and women. In women, higher visceral fat was additionally linked to shorter telomere length.
“Our study shows that visceral fat is associated with faster biological and cellular ageing,” said Associate Professor Hui, who is Director of the Busselton Health Study Laboratory. “Understanding what drives faster ageing helps us find better ways to stay healthy for longer.”
An effect that holds after adjusting for other body measures
A central finding of the study is that the link between visceral fat and accelerated ageing persisted even when researchers controlled for other indicators commonly used to assess body composition and adiposity.
“Importantly, these associations remained significant even after accounting for overall body fat, body mass index, waist circumference and lifestyle factors,” Associate Professor Zhu said.
This suggests that visceral fat may have implications for ageing that are not fully captured by routine measures such as BMI or waist circumference – measures that have long been criticised for failing to distinguish between fat stored just under the skin and the metabolically distinct fat located deep within the abdomen.
Why visceral fat behaves differently
Visceral fat is biologically active in ways that subcutaneous fat is not. It secretes inflammatory signalling molecules and contributes to a chronic, low-grade inflammatory state that researchers have increasingly linked to chronic disease and accelerated ageing.
“Visceral fat is metabolically active, secreting a range of pro-inflammatory proteins, which contribute to systemic inflammation and metabolic stress,” Associate Professor Zhu said.
She also noted a practical point that is likely to resonate in clinical settings: visceral fat does not require specialised, costly imaging to assess. “It can be easily measured using imaging technology, which is widely used in routine bone density scans,” she said. This positions visceral fat as a metric that could plausibly be folded into existing clinical workflows without significant additional cost.
The value of long-running cohort data
The findings rest on one of the most established population-health datasets in the world. Established in 1966, the Busselton Health Study is internationally recognised as one of the longest-running population health programmes ever conducted, providing a rich longitudinal dataset that continues to support research into chronic disease and healthy ageing.
Mr O’Shea, who led the analysis, said the project demonstrated the enduring scientific value of sustained cohort studies of this kind. “Access to high-quality longitudinal data allowed us to better understand how clinical risk factors relate to long-term health outcomes,” he said.
Implications for healthier ageing
The findings reinforce a growing body of evidence that abdominal fat distribution – not just total body fat – is an important consideration in healthy ageing. While the study is observational and does not establish that reducing visceral fat will directly slow ageing, the authors argue the results support the case for targeting abdominal fat as part of broader strategies to promote healthier ageing in middle and later life.
For clinicians, the practical takeaway is that visceral fat may warrant attention even in people whose BMI or waist circumference appears unremarkable, and that the imaging tools needed to measure it are already widely available in routine care.
The study, “Visceral fat is associated with accelerated biological and cellular ageing,” is published in Obesity.
Read More
Obesity-Related Fat Tissue Signals Identified as a Driver of Age-Related Muscle Loss
Key Takeaways:
- Researchers have identified a biological mechanism linking obesity-related fat tissue to accelerated muscle loss in older adults.
- Tiny particles released by adipose tissue were shown to directly trigger muscle atrophy in ageing human muscle cells.
- Younger muscle appears biologically protected from these effects, highlighting an age-dependent vulnerability that may inform future therapies.
New insight into sarcopenic obesity
Researchers at the University of Birmingham have identified a previously unrecognised biological pathway through which obesity may contribute to muscle loss in older adults. The findings provide important new insight into sarcopenic obesity, a condition in which excess body fat exists alongside reduced muscle mass and strength.
The study, published in the Journal of Cachexia, Sarcopenia and Muscle and conducted through the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC), demonstrates for the first time that signals released from adipose tissue can directly induce muscle wasting in human cells.
Sarcopenic obesity is becoming increasingly common as populations age and is associated with frailty, impaired mobility and poorer overall health outcomes. The condition is estimated to affect approximately 11% of the population.
Fat tissue communication with muscle
The research focused on extracellular vesicles – microscopic particles released by fat tissue that act as biological messengers between organs and tissues.
Investigators discovered that extracellular vesicles derived specifically from obese adipose tissue, rather than lean tissue, caused significant thinning of muscle fibres obtained from older adults. This thinning represents a hallmark feature of muscle atrophy.
The harmful effects were traced to molecular cargo carried within these vesicles, particularly miR-150-5p, a microRNA known to regulate gene expression pathways involved in maintaining muscle structure and function.
These findings suggest that obesity does not simply increase fat mass but fundamentally alters how adipose tissue behaves and communicates with other organs, including skeletal muscle.
Age-dependent vulnerability of muscle
A notable finding of the study was that muscle cells derived from younger adults showed resistance to these obesity-related signals.
When exposed to extracellular vesicles from obese adipose tissue, younger muscle cells did not undergo the same degree of thinning observed in older muscle cells. This indicates that ageing muscle becomes biologically more susceptible to inflammatory and metabolic signals associated with obesity.
Speaking about the findings, first author Dr Joshua Price, Postdoctoral Researcher, explained:
“It isn’t just having more fat tissue that matters. Obesity changes how fat tissue behaves and how it communicates with muscle. Ageing muscle is far more vulnerable to these altered signals, which helps explain why muscle loss accelerates with obesity later in life.”
Identifying a potential therapeutic target
The identification of miR-150-5p as a key molecular driver presents a potential opportunity for therapeutic intervention. Researchers found that inhibiting this microRNA could partially reduce the muscle-wasting effects observed in laboratory models.
Overall, the results suggest a dual biological reality – younger muscle demonstrates protective resilience, while ageing muscle becomes increasingly vulnerable to obesity-related signalling pathways.
Senior author Professor Simon Jones, Professor in Musculoskeletal Ageing at the University of Birmingham and lead for the NIHR Birmingham BRC’s Sarcopenia and Multimorbidity research theme, said:
“Through this research, we’ve identified a key molecular pathway by which obesity can accelerate muscle loss in older adults. Importantly, we found that younger muscle appears resilient to these harmful signals, whereas ageing muscle becomes more vulnerable. This reinforces the importance of maintaining a healthy weight and muscle health as we age.”
He added:
“Our findings also open two potential therapeutic avenues: either blocking or modifying the harmful extracellular vesicles released from obese tissue, or developing strategies to make older muscle more resilient, mimicking the protective effects seen in younger muscle.”
Implications for ageing and obesity care
The study strengthens understanding of how ageing and obesity interact at a cellular level to influence physical decline. Rather than viewing muscle loss solely as a consequence of ageing or inactivity, the findings highlight obesity-related biological signalling as an active contributor.
By demonstrating that altered communication between fat and muscle tissue can directly drive muscle atrophy, the research provides a clearer mechanistic explanation for why people living with obesity may experience accelerated functional decline later in life.
The work was delivered through the NIHR Birmingham Biomedical Research Centre, with Dr Joshua Price serving as a BRC-funded postdoctoral research associate within the Sarcopenia and Multimorbidity research theme.
Together, these findings may support future strategies aimed at preserving muscle health in ageing populations, particularly among people living with obesity, where preventing muscle loss is critical for maintaining independence, mobility and long-term health outcomes.
Read More
Genetic Study Establishes Causal Link Between Obesity and Dementia
Key Takeaways:
- New genetic evidence suggests that higher body weight and elevated blood pressure play a direct causal role in the development of dementia.
- The findings indicate that addressing obesity and high blood pressure earlier in life may offer an important opportunity for dementia prevention.
- Much of the increased dementia risk associated with higher body weight appears to be driven by high blood pressure, highlighting a potentially modifiable pathway.
Obesity, blood pressure and dementia risk
People living with obesity and high blood pressure may face a higher risk of developing dementia, according to a new study published in The Journal of Clinical Endocrinology & Metabolism. The research adds to a growing body of evidence linking cardiovascular and metabolic health to long-term brain health.
Dementia represents a major and escalating global public health challenge. There is currently no cure, and people living with dementia experience a progressive decline in mental abilities, including memory, thinking and reasoning. Over time, this decline can significantly impair daily functioning and independence.
The most common forms of dementia include Alzheimer’s disease, vascular dementia and mixed dementia. Although these conditions vary in their underlying pathology, all involve progressive damage to nerve cells in the brain, leading to worsening problems with memory, language, problem-solving and behaviour.
Study identifies a causal relationship
The study was led by Ruth Frikke-Schmidt, M.D., Ph.D., Professor and Chief Physician at Copenhagen University Hospital – Rigshospitalet and the University of Copenhagen.
“In this study, we found high body mass index (BMI) and high blood pressure are direct causes of dementia,” said Frikke-Schmidt. “The treatment and prevention of elevated BMI and high blood pressure represent an unexploited opportunity for dementia prevention.”
Researchers analysed genetic and health data from participants in Copenhagen and the UK. Their analysis revealed a clear causal link between higher body weight and an increased risk of dementia.
How Mendelian randomisation strengthened the findings
The researchers were able to establish a direct causal relationship by using a Mendelian randomisation study design, which closely mimics the structure of a randomised controlled trial.
In Mendelian randomisation, naturally occurring genetic variants associated with higher BMI are used as proxies for lifelong exposure to higher body weight. Because these genetic variants are randomly inherited from parents to offspring, their distribution is not influenced by lifestyle, socioeconomic status or other confounding factors.
This process mirrors the random assignment of participants to treatment or placebo groups in drug trials. As a result, any differences in dementia outcomes between individuals with BMI-increasing genetic variants and those without can be more confidently attributed to body weight itself, rather than to external influences.
Using this approach, the researchers were able to demonstrate that higher BMI plays a direct causal role in increasing the risk of dementia.
Blood pressure emerges as a key driver
Further analysis suggested that much of the increased dementia risk associated with higher body weight was driven by elevated blood pressure. This finding points to a potential pathway through which obesity may contribute to cognitive decline.
By implication, preventing or effectively treating obesity and high blood pressure could help reduce the risk of dementia, particularly forms linked to vascular damage in the brain.
“This study shows that high body weight and high blood pressure are not just warning signs, but direct causes of dementia. That makes them highly actionable targets for prevention,” said Frikke-Schmidt.
Implications for prevention and future research
The findings also raise important questions about the timing of weight management interventions. While weight-loss medications have recently been tested in people with early-stage Alzheimer’s disease, these trials have not shown clear benefits for halting cognitive decline once symptoms are established.
“Weight-loss medication has recently been tested for halting cognitive decline in early phases of Alzheimer’s disease, but with no beneficial effect,” Frikke-Schmidt said. “An open question that remains to be tested is if weight-loss medication initiated before the appearance of cognitive symptoms may be protective against dementia. Our present data would suggest that early weight-loss interventions would prevent dementia, and especially vascular-related dementia.”
Together, the results reinforce the importance of addressing obesity and high blood pressure not only to protect cardiovascular health, but also as part of a broader strategy to reduce the long-term risk of dementia.
Read More
Study Suggests GLP-1 Medications May Reduce Frailty Progression in Older Adults
Key Takeaways:
- Older adults with type 2 diabetes who begin SGLT-2 inhibitors or GLP-1 receptor agonists show slower frailty progression over one year compared with those starting other diabetes therapies.
- The analysis, based on a large national Medicare dataset, suggests these medications may offer benefits beyond glycaemic and cardiovascular control, potentially supporting strength, mobility, and functional independence.
- The protective effect was not fully explained by fewer cardiovascular or safety events, indicating a possible direct influence of these drug classes on frailty itself.
Emerging evidence that newer diabetes drugs may protect against frailty
A new study has found that older adults living with type 2 diabetes who initiate treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors or glucagon-like peptide-1 (GLP-1) receptor agonists experience significantly slower progression of frailty over a 12-month period compared with those starting alternative diabetes medications. The findings point to a potential added advantage of these therapies in helping older adults maintain physical resilience, strength, and independence, complementing their established effects on blood glucose regulation and cardiovascular risk reduction.
Study overview and methods
The research, published in Diabetes Care and titled “Sodium–Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Frailty Progression in Older Adults With Type 2 Diabetes”, examined a large national cohort of older adults in the United States who had recently begun different classes of diabetes medication.
The investigators analysed a 7 per cent sample of Medicare claims data, enabling real-world tracking of over one year of health outcomes. Frailty progression was assessed using a validated claims-based Frailty Index (CFI), which ranges from 0 to 1 and reflects the cumulative presence of age-related health deficits. Higher CFI scores indicate more severe frailty.
Key findings – slower frailty progression with SGLT-2 and GLP-1 therapies
Older adults newly prescribed a GLP-1 receptor agonist, such as semaglutide (Ozempic) or liraglutide (Victoza), demonstrated a mean CFI change of –0.007 (95 per cent CI: –0.011 to –0.004) compared with matched new users of DPP-4 inhibitors. Those initiating SGLT-2 inhibitors, including empagliflozin (Jardiance) and dapagliflozin (Farxiga), experienced a mean change of –0.005 (95 per cent CI: –0.008 to –0.002).
These figures represent a statistically significant slowing in frailty progression over the study period. In contrast, people beginning sulfonylureas did not show a meaningful difference relative to DPP-4 inhibitor users.
Importantly, the study found that cardiovascular events and other safety-related health issues explained only a small proportion of the protective association. This suggests that these classes of medications may exert a more direct biological effect on mechanisms related to frailty, such as inflammation, physical function, or metabolic stress.
Why frailty matters in older adults with type 2 diabetes
Frailty is common among older adults and especially prevalent in people living with type 2 diabetes. Previous research indicates that 10–15 per cent of adults over the age of 65 meet criteria for frailty, with substantially higher rates among those with diabetes. Multiple factors contribute to this increased vulnerability, including chronic low-grade inflammation, accelerated muscle loss, cardiovascular disease, and the overall physiological strain of managing a long-term condition.
Frailty is linked to an elevated risk of falls, disability, hospital admission, diminished quality of life, and reduced survival. Because frailty is difficult to reverse once it becomes established, clinicians and researchers have prioritised strategies that can delay or slow its progression. The study’s findings therefore hold particular significance for geriatric diabetes care.
Clinical implications – a possible shift in medication decision-making
The results may encourage clinicians to consider the broader health trajectory of older adults when selecting diabetes medications, especially as SGLT-2 inhibitors and GLP-1 receptor agonists are increasingly used for combined glycaemic, cardiovascular, and renal protection.
Chanmi Park, MD, MPH, the study’s lead author and Assistant Scientist I at the Hinda and Arthur Marcus Institute for Aging Research at Hebrew SeniorLife, highlighted this point:
“While SGLT-2 inhibitors and GLP-1 receptor agonists are primarily prescribed for blood sugar control and heart protection, our findings show they may also help older adults with diabetes stay stronger and less vulnerable to health setbacks. Because frailty is common, serious, and hard to reverse, this could meaningfully change how clinicians think about medication choices for ageing patients.”
A promising step towards more holistic diabetes care
The study adds to a growing body of literature suggesting that newer diabetes medications may offer multidimensional benefits. By potentially supporting physical resilience in addition to metabolic and cardiovascular health, SGLT-2 inhibitors and GLP-1 receptor agonists could become central tools in promoting healthier ageing for people living with type 2 diabetes.
Further research will be needed to better understand the biological mechanisms at play and to determine whether similar benefits appear in more diverse patient populations and longer-term studies.
CCH insight:
The results of this study are very encouraging from the perspective of GLP-1 medications and muscle mass/strength. There are currently concerns in some quarters about potential excess loss of muscle mass and sarcopenia accompanying weight loss from these drugs. However, this study points towards a positive impact on physical strength and function from GLP-1 therapy.
Read More
Age and Sex Shape Obesity’s Impact on Major Diseases, Large Genetic Study Finds
Key Takeaways:
- A time-resolved genetic analysis of over 360,000 UK Biobank participants shows that obesity’s health risks vary substantially across age and between men and women.
- Higher BMI was causally linked to greater risk of type 2 diabetes, coronary artery disease, atrial fibrillation, and osteoarthritis, but the timing and intensity of these effects differed by condition.
- The study’s novel genetic approach revealed that preventive interventions such as statin or blood pressure treatment may temporarily dampen obesity-related cardiovascular risk in midlife.
Understanding obesity’s changing health risks
Nearly one billion adults globally live with obesity, making it a key driver of type 2 diabetes (T2DM), coronary artery disease (CAD), atrial fibrillation (AF), and osteoarthritis (OA). Yet researchers have long struggled to pinpoint when in life excess body weight does the most harm.
Most studies average risk across all adults, masking crucial age-specific patterns. Body mass index (BMI) remains the standard measure of obesity, but its health impact may shift as metabolism, hormones, behaviour, and medical care evolve through life. Moreover, traditional epidemiological studies cannot always distinguish correlation from causation.
Genetic studies using Mendelian randomisation (MR) can infer causal effects, but conventional MR assumes that risks remain constant over time. In a new paper published in Science Advances, researchers introduced a time-resolved MR framework that tracks how obesity’s effects on major diseases change with age and differ between sexes.
Study design and methods
The researchers analysed data from 361,906 unrelated adults of European ancestry within the UK Biobank, a large population-based health resource. Participants had linked genetic and medical record data, and follow-up continued until a median age of around 70 years, capped at 76 to avoid sparse data at older ages.
BMI at study entry was standardised within sex-by-age groups. The primary outcomes were first occurrences of T2DM, CAD, AF, and OA, identified using International Classification of Diseases (ICD-10) codes.
To establish causal relationships, the team employed MR using polygenic scores (PGS) as instruments. They performed genome-wide association studies (GWAS) for BMI in two independent subsamples (each ~180,953 participants) to identify genome-wide significant genetic variants.
To minimise reverse causation, disease-specific BMI PGS were filtered using the Steiger method, which excluded variants that explained more variation in disease outcomes than in BMI itself. The researchers then modelled time-to-event data using Aalen’s additive hazard model, estimating both cumulative (“life-course”) and age-specific (“momentary”) effects.
Sensitivity analyses accounted for potential biases, including lipid-lowering treatment among CAD-free participants, blood pressure (SBP) as an alternative exposure, and cohort selection effects.
Distinct patterns across diseases
Across adulthood, higher BMI was causally associated with increased rates of all four conditions, but with striking differences in timing and trajectory.
- Osteoarthritis (OA): BMI-related risk rose early in life, becoming significant over 20 years before risk for AF increased. This suggests that musculoskeletal strain and inflammatory pathways linked to obesity manifest relatively early.
- Atrial Fibrillation (AF): The risk associated with BMI intensified later in adulthood, suggesting that atrial and metabolic factors accumulate over time.
- Type 2 Diabetes (T2DM): The effect of BMI increased steadily from midlife but plateaued between ages 60 and 70, indicating that preventive measures or clinical interventions may mitigate risk during this period.
- Coronary Artery Disease (CAD): The most distinctive pattern emerged here – a U-shaped curve. Risk decreased markedly around ages 50 to 70 before rising again in older age. This midlife dip was not explained by study participation patterns but appeared more pronounced among individuals on lipid-lowering medication such as statins, suggesting that treatment may blunt BMI-related cardiovascular risk during this window.
When the researchers replaced BMI with systolic blood pressure (SBP) as the exposure, AF risk displayed a similar midlife trough, consistent with the effect of antihypertensive therapy. However, no comparable trough appeared for CAD, reinforcing the role of statins rather than blood pressure control in midlife coronary risk reduction.
Sex differences in risk
Sex-stratified analyses revealed generally stronger BMI effects in men for T2DM, CAD, and AF. Osteoarthritis was an exception: both sexes exhibited similar BMI-related risk until about age 60, after which the association appeared to decline slightly in women, although the results carried uncertainty due to diverging confidence intervals.
A particularly notable finding concerned T2DM. Women displayed a distinct, temporary reduction in BMI-related diabetes risk beginning around age 60 and lasting roughly a decade, whereas men’s risk continued to rise. This “female trough” was not accounted for by menopause timing or the use of hormone therapy, suggesting that behavioural or clinical factors – such as greater engagement with weight management or preventive health care – could play a role.
Genetic and methodological insights
Clustering of BMI-associated genetic variants revealed multiple mechanistic pathways underlying obesity’s effects. Different genetic clusters contributed distinct temporal risk patterns for CAD and T2DM. For instance, “high-risk” clusters largely accounted for the CAD trough and the sex differences seen in T2DM.
Importantly, the researchers verified that the strength of genetic effects on BMI declines with age, underscoring the need for age-sensitive models. Simulation studies confirmed that their time-resolved MR method accurately captured dynamic effects even when the genetic influence on BMI varied over time.
Adjustments for potential selection bias slightly reduced the overall magnitude of effects but preserved key age-related patterns, including the midlife risk reductions.
Clinical implications
The findings emphasise that the timing of prevention matters as much as the magnitude of obesity itself. Sustained high BMI elevates the risk for several major diseases, but the most effective period for intervention differs by condition and by sex.
For example:
- Lipid-lowering treatment in midlife may attenuate BMI-related CAD risk.
- Blood pressure control could moderate AF risk later in life.
- Women may experience a unique window in their 60s when obesity-related diabetes risk temporarily subsides.
The authors conclude that prevention strategies should be tailored to life stage and sex, targeting the periods when intervention can avert the greatest number of disease events.
They also note limitations, including the assumption of an immediate biological response to BMI changes and the reduced precision of genetic instruments for early-life BMI. Nonetheless, their time-resolved MR framework offers a powerful new approach for uncovering dynamic, age-specific health risks that static analyses may obscure.
Read More
Severe Obesity Accelerates Lung Ageing by Altering Tissue Structure, Study Finds
Key Takeaways:
- Researchers at the University of Bonn have shown that severe obesity causes structural and molecular changes in lung tissue that mimic those of natural ageing.
- Obesity leads to the accumulation of fat within lung connective tissue cells, disrupting their normal function and reducing lung elasticity.
- These findings help explain why people living with obesity often experience breathing difficulties and may face a higher risk of lung-related complications.
Obesity found to accelerate ageing in the lungs
A research team led by Professor Dr Veronika Lukacs-Kornek from the ImmunoSensation2 Cluster of Excellence at the University of Bonn and the Institute for Molecular Medicine and Experimental Immunology (IMMEI) at the University Hospital Bonn (UKB) has discovered that severe obesity causes the lungs to age prematurely. The findings, published in Cell Reports, shed new light on how excessive body weight affects lung function and structure at the molecular level.
The study explored how the lungs respond to nutritional challenges associated with obesity, revealing that excess body fat significantly remodels the extracellular matrix (ECM) – the protein-based “scaffolding” that provides the lungs with their shape, strength, and stability. These alterations in lung architecture closely resemble those typically observed during the natural ageing process, suggesting that obesity accelerates the biological ageing of lung tissue.
Multi-omics analysis reveals profound structural changes
To investigate these effects, the researchers employed state-of-the-art multi-omics techniques – a set of advanced tools that allow for the simultaneous study of proteins, lipids, and genes. This integrative approach enabled the team to map how obesity influences the lungs at multiple biological levels.
By combining molecular analyses with microscopic imaging and functional experiments that tested how lungs perform, the team was able to capture a comprehensive picture of obesity’s impact. They compared the lungs of obese and lean mice, examined human lung fibroblasts (connective tissue cells), and studied the overall composition of lung tissue to identify both molecular and functional differences.
Fat accumulation and loss of elasticity in lung tissue
The results showed that in obesity, lung fibroblasts – the cells responsible for maintaining the connective tissue – begin to accumulate fat, becoming more mobile and displaying early signs of premature ageing. At the same time, the matrisome, which refers to the entire collection of ECM proteins, undergoes significant changes.
These changes disturb the delicate balance of protease inhibitors, enzymes that regulate tissue maintenance and repair. As a consequence, the lungs become less elastic and more prone to stiffness. This reduced elasticity helps explain why people living with obesity often experience shortness of breath and other respiratory difficulties.
“Interestingly, these changes are similar to those normally seen in older people – pointing to obesity as a driver of accelerated lung ageing,” the authors noted.
Overcoming complex research challenges
Studying the lung’s connective tissue presented major technical challenges. The fibroblastic stroma – the supportive framework of the lungs – comprises numerous cell types with highly specialised roles, making it difficult to isolate and analyse. Furthermore, the extracellular matrix itself is notoriously complex: many of its proteins are insoluble and possess intricate structures that resist standard laboratory analysis.
To address this, the team had to develop novel analytical methods that could overcome these limitations and enable the simultaneous study of multiple molecular components within the tissue. This innovative approach has allowed researchers to better understand how obesity-induced changes at the cellular level translate into functional impairments in lung performance.
Implications for understanding obesity-related lung disease
The study provides compelling evidence that obesity accelerates biological ageing processes in the lungs, underscoring the broader systemic impact of excess body weight beyond metabolic and cardiovascular complications.
By demonstrating that obesity alters both the composition and function of lung tissue, the findings open new avenues for exploring how weight management and metabolic interventions might help preserve lung health and mitigate premature ageing in people living with obesity.
CCH insight:
This is an interesting study. It shows that shortness of breath in people with obesity is not simply a case of poor cardiorespiratory fitness or due to mechanical difficulties due to accumulation of adipose tissue in the chest – it actually involves structural changes to lung tissue, similar to biological aging. It would be interesting to compare the lung tissue of people with obesity who have a sedentary inactive lifestyle with that of people with obesity who are active and physically fit, to see if exercise and better cardiorespiratory fitness can prevent these tissue changes and premature aging of the lungs.
Read More